Literature DB >> 29134355

Extracellular contrast agent-enhanced MRI: 15-min delayed phase may improve the diagnostic performance for hepatocellular carcinoma in patients with chronic liver disease.

Si Eun Lee1, Chansik An2, Shin Hye Hwang1, Jin-Young Choi1, Kyunghwa Han1, Myeong-Jin Kim1.   

Abstract

OBJECTIVES: To determine the value of a 15-min delayed phase in extracellular contrast agent (ECA)-enhanced magnetic resonance imaging (MRI) for evaluation of hepatocellular carcinoma (HCC) in patients with chronic liver disease.
METHODS: Between 2014 and 2015, 103 patients with chronic liver disease underwent ECA-enhanced MRI; 133 lesions consisting of 107 HCCs, 23 benign lesions and three non-HCC malignancies were identified with pathological or clinical diagnosis. MRI images were reviewed by two abdominal radiologists independently using the European Association for the Study of the Liver (EASL) and Liver Imaging Reporting and Data System (LI-RADS) criteria. Imaging features observed in the 15-min delayed phase were recorded.
RESULTS: Of 107 HCCs, three or four additional HCCs were diagnosed according to the EASL criteria by adding the 15-min delayed phase, increasing sensitivity (Reviewer 1, from 69.2-72.0 % [P = 0.072]; Reviewer 2, from 75.7-79.4 % [P = 0.041]). Reviewers 1 and 2 upgraded one and four HCCs from LR-4 to LR-5 based on the LI-RADS, respectively. Among 23 benign lesions, no additional findings were observed in the 15-min delayed phase.
CONCLUSIONS: Including the 15-min delayed phase in ECA-enhanced MRI may improve the diagnostic performance for HCC in patients with chronic liver disease. KEY POINTS: • Additional acquisition of 15-min delayed phase (FDP) requires approximately 20 s. • About 5 % of HCCs show washout or capsule appearance only in FDP. • Including FDP improves the sensitivity of extracellular contrast agent-enhanced MRI for HCC. • These results are applicable only to patients with chronic liver disease.

Entities:  

Keywords:  15-minute delayed phase; Gadolinium DTPA; Gadoterate meglumine; Hepatocellular carcinoma; Magnetic resonance imaging

Mesh:

Substances:

Year:  2017        PMID: 29134355     DOI: 10.1007/s00330-017-5119-y

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  32 in total

1.  Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients.

Authors:  Sith Phongkitkarun; Kuruwin Limsamutpetch; Penampai Tannaphai; Janjira Jatchavala
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

2.  Liver Imaging Reporting and Data System on CT and gadoxetic acid-enhanced MRI with diffusion-weighted imaging.

Authors:  Dong Ik Cha; Kyung Mi Jang; Seong Hyun Kim; Tae Wook Kang; Kyoung Doo Song
Journal:  Eur Radiol       Date:  2017-04-03       Impact factor: 5.315

3.  Gadoxetate disodium-enhanced MRI of mass-forming intrahepatic cholangiocarcinomas: imaging-histologic correlation.

Authors:  Hyeon Tae Jeong; Myeong-Jin Kim; Yong Eun Chung; Jin Young Choi; Young Nyun Park; Ki Whang Kim
Journal:  AJR Am J Roentgenol       Date:  2013-10       Impact factor: 3.959

4.  Small hepatocellular carcinoma and cavernous hemangioma: differentiation with dynamic FLASH MR imaging with Gd-DTPA.

Authors:  H Yoshida; Y Itai; K Ohtomo; T Kokubo; M Minami; N Yashiro
Journal:  Radiology       Date:  1989-05       Impact factor: 11.105

5.  Cholangiocarcinoma: delayed CT contrast enhancement patterns.

Authors:  J M Lacomis; R L Baron; J H Oliver; M A Nalesnik; M P Federle
Journal:  Radiology       Date:  1997-04       Impact factor: 11.105

6.  MR imaging patterns of gadolinium retention within liver neoplasms.

Authors:  M S Peterson; T Murakami; R L Baron
Journal:  Abdom Imaging       Date:  1998 Nov-Dec

7.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

8.  Liver imaging reporting and data system (LI-RADS) version 2014: understanding and application of the diagnostic algorithm.

Authors:  Chansik An; Gulbahor Rakhmonova; Jin-Young Choi; Myeong-Jin Kim
Journal:  Clin Mol Hepatol       Date:  2016-06

9.  ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents.

Authors:  E Neri; M A Bali; A Ba-Ssalamah; P Boraschi; G Brancatelli; F Caseiro Alves; L Grazioli; T Helmberger; J M Lee; R Manfredi; L Martì-Bonmatì; C Matos; E M Merkle; B Op De Beeck; W Schima; S Skehan; V Vilgrain; C Zech; C Bartolozzi
Journal:  Eur Radiol       Date:  2015-07-21       Impact factor: 5.315

10.  Cost evaluation of gadoxetic acid-enhanced magnetic resonance imaging in the diagnosis of colorectal-cancer metastasis in the liver: Results from the VALUE Trial.

Authors:  Christoph J Zech; Nahila Justo; Andrea Lang; Ahmed Ba-Ssalamah; Myeong-Jin Kim; Harald Rinde; Eduard Jonas
Journal:  Eur Radiol       Date:  2016-02-24       Impact factor: 5.315

View more
  3 in total

1.  Gadoxetic acid-enhanced MRI for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: can hypointensity on the late portal venous phase be used as an alternative to washout?

Authors:  Kyoung A Baek; Seung Soo Kim; Hyeong Cheol Shin; Jeong Ah Hwang; Seo-Youn Choi; Woong Hee Lee; Chan Ho Park; Hyoung Nam Lee; Nam Hun Heo
Journal:  Abdom Radiol (NY)       Date:  2020-09

2.  Evaluation of liver tumor identification rate of volumetric-interpolated breath-hold images using the compressed sensing method and qualitative evaluation of tumor contrast effect via visual evaluation.

Authors:  Daisuke Yoshimaru; Yoich Araki; Chifumi Matsuda; Natsuhiko Shirota; Yu Tajima; Shuhei Shibukawa; Katsutoshi Murata; Dominik Nickel; Kazuhiro Saito
Journal:  Quant Imaging Med Surg       Date:  2022-05

Review 3.  Liver Imaging Reporting and Data System (LI-RADS) Version 2018: Imaging of Hepatocellular Carcinoma in At-Risk Patients.

Authors:  Victoria Chernyak; Kathryn J Fowler; Aya Kamaya; Ania Z Kielar; Khaled M Elsayes; Mustafa R Bashir; Yuko Kono; Richard K Do; Donald G Mitchell; Amit G Singal; An Tang; Claude B Sirlin
Journal:  Radiology       Date:  2018-09-25       Impact factor: 11.105

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.